GLP-1 receptor agonists, which can cost around $1,300 a month, have caused an increase in premiums that “affect all members, ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better ...

The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...

The market for injectable weight loss medications has experienced rapid growth. Goldman Sachs Research predicts the global ...

The FDA has approved Eli Lillys Zepbound as the first weight-loss drug to treat obstructive sleep apnea, reshaping care for ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to ...

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...

Obesity continues to plague New Yorkers, affecting almost two out of every three adults in our state. That’s why I’m pushing ...

Richard Saynor sees opportunity in copying cutting-edge medication and extols the merits of being boring. Richard Saynor ...

New research found that some anti-obesity medications such as Wegovy and Zepbound may prompt people to drink less. These ...

Now, research from Henry Ford Health, has found that weight-loss drugs, including GLP-1, could also impact alcohol ...